NVO - DaVita stock sell-off over Ozempic study big overreaction says UBS
2023-10-11 10:03:52 ET
More on DaVita
- DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
- DaVita Inc. (DVA) Q2 2023 Earnings Call Transcript
- DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold
- Dialysis stocks tumble in wake of Ozempic kidney failure study update
For further details see:
DaVita stock sell-off over Ozempic study "big overreaction," says UBS